Get started
iShares Biotechnology ETFiShares Biotechnology ETFiShares Biotechnology ETF

iShares Biotechnology ETF

No trades
See on Supercharts
Overview Analysis Holdings News
Ideas
Discussions Technicals Seasonals Options

IBB trade ideas

10 Small-Cap Biotechs with Key Catalysts for 2025 July List________________________________________ 🔬 10 Small-Cap Biotechs with Key Catalysts for 2025 July List ________________________________________ 1. Allogene Therapeutics (NASDAQ: ALLO) • Catalyst: Phase 2 data for ALLO-501A (anti-CD19 CAR-T for large B-cell lymphoma) expected in H2 2025; potential pivotal data could lead to regulatory submission. • Highlights: “Off-the-shelf” allogeneic CAR-T approach could transform cell therapy; watch for manufacturing/scalability updates. ________________________________________ 2. Lixte Biotechnology (NASDAQ: LIXT) • Catalyst: Phase 2 combo trial of LB-100 (PP2A inhibitor) + immunotherapy in solid tumors, with key data expected in late 2025. • Highlights: If efficacy signals emerge, could prompt partnerships or additional trials. ________________________________________ 3. Iovance Biotherapeutics (NASDAQ: IOVA) • Catalyst: Commercial launch and sales uptake for AMTAGVI (lifileucel, first FDA-approved TIL therapy in advanced melanoma); upcoming label expansion studies in lung and cervical cancer. • Highlights: Investor focus on launch ramp, real-world data, and new trial initiations in 2025. ________________________________________ 4. RenBio (NASDAQ: RENB) • Catalyst: Phase 1/2 data for RB-100 (bispecific antibody platform in solid tumors) expected mid-to-late 2025. • Highlights: Pipeline progress and partnership announcements possible. ________________________________________ 5. IGM Biosciences (NASDAQ: IGMS) • Catalyst: Phase 2 data for IGM-2323 (CD20 x CD3 bispecific in non-Hodgkin lymphoma) expected early 2025; ongoing updates from IgM antibody platform. • Highlights: Investor interest in clinical safety, efficacy, and potential for big pharma tie-ups. ________________________________________ 6. Zura Bio (NASDAQ: ZURA) • Catalyst: Phase 2b/3 trial start and topline data for tibulizumab (IL-7Ra mAb for autoimmune diseases) expected late 2025. • Highlights: Focus on rare and orphan autoimmune indications. ________________________________________ 7. INmune Bio (NASDAQ: INMB) • Catalyst: Phase 2 Alzheimer’s data (XPro1595, targeting neuroinflammation) and oncology pipeline updates expected H1 2025. • Highlights: Any signal in Alzheimer’s is high-impact; monitoring for FDA guidance. ________________________________________ 8. Veru Inc (NASDAQ: VERU) • Catalyst: Phase 3 trial results for enobosarm (oral SARM) in advanced breast cancer expected 2025; also, COVID/sepsis drug updates. • Highlights: Regulatory clarity and partnership/M&A rumors are potential drivers. ________________________________________ 9. Century Therapeutics (NASDAQ: IPSC) • Catalyst: First-in-human data for iPSC-derived NK and CAR-T cell therapies, with updates expected at major meetings in 2025. • Highlights: Platform validation and early efficacy/safety signals. ________________________________________ 10. ProKidney (NASDAQ: PROK) • Catalyst: Phase 3 pivotal data for REACT (cell therapy for chronic kidney disease/diabetes) due late 2025. • Highlights: If positive, could become the first autologous cell therapy for kidney disease. ________________________________________ 🔎 How to Monitor These Catalysts • FDA submissions/meetings (ALLO, PROK, VERU) • Clinical trial readouts (LIXT, RENB, IGMS, ZURA, INMB, IPSC) • Commercial/launch data (IOVA) • Partnership/M&A activity (IGMS, VERU, RENB) ________________________________________ 📊 Summary Table Ticker Company Upcoming Catalyst/Event Timeframe ALLO Allogene Therapeutics Phase 2 LBCL CAR-T pivotal data H2 2025 LIXT Lixte Biotechnology LB-100 + immunotherapy Phase 2 data Late 2025 IOVA Iovance Biotherapeutics AMTAGVI launch data; label expansions Throughout 2025 RENB RenBio Bispecifics Phase 1/2 data Mid-to-late 2025 IGMS IGM Biosciences IGM-2323 Phase 2 data (lymphoma) Early 2025 ZURA Zura Bio Tibulizumab Phase 2b/3 topline data Late 2025 INMB INmune Bio Alzheimer’s/oncology trial updates H1 2025 VERU Veru Inc Enobosarm Phase 3 (breast cancer) 2025 IPSC Century Therapeutics First-in-human iPSC cell therapy data 2025 PROK ProKidney REACT Phase 3 (CKD) pivotal readout Late 2025 ________________________________________ ⚠️ Word of Caution Small-cap biotech stocks can be extremely volatile, especially around catalyst events (trial data, FDA decisions). Sharp price swings—both up and down—are common. Always conduct your own research and be aware of the risks.
NASDAQ:IBBLong
by ProjectSyndicate
31
Top 10 Small-Cap Biotechs with Upcoming Catalysts for 2025Here are 10 small cap biotech stocks with notable upcoming catalysts in 2025—ranging from trial readouts and FDA decisions to pivotal data and corporate milestones: ________________________________________ 🔬 Top 10 Small-Cap Biotechs with Upcoming Catalysts for 2025 1. Crinetics Pharmaceuticals (NASDAQ: CRNX) • Catalyst: FDA PDUFA deadline for paltusotine (oral acromegaly treatment) expected by September 25, 2025. • Focused on endocrine diseases and advancing pipeline beyond acromegaly (en.wikipedia.org). Stock market information for Crinetics Pharmaceuticals Inc (CRNX) • Crinetics Pharmaceuticals Inc is a equity in the USA market. • The price is 32.33 USD currently with a change of -0.73 USD (-0.02%) from previous close. • The latest open price was 33.1 USD and the intraday volume is 420639. • The intraday high is 33.34 USD and the intraday low is 32.32 USD. • The latest trade time is Wednesday, June 11, 23:45:00 +0300. ________________________________________ 2. Viking Therapeutics • Catalyst: Late-stage trial start for injectable weight-loss drug (GLP 1/GIP); mid-stage data readout for oral candidate due in 2025 (barrons.com). • Strong analyst sentiment: Jefferies forecasts ~223% upside ________________________________________ 3. Insmed (NASDAQ: INSM) • Catalyst: Phase III/inhalable powder treprostinil palmitil for pulmonary arterial hypertension; recent results exceeded expectations; full Phase III data due in 2025 ________________________________________ 4. Kymera Therapeutics • Catalyst: Phase I for KT 621 (oral STAT6 degrader for dermatitis/asthma); next-stage readouts expected late 2025–early 2026 • Shares rose ~50% on initial results; further trials underway ________________________________________ 5. Arcutis Biotherapeutics (NASDAQ: ARQT) • Catalyst: Technical breakout potential near $17.75; continued quarterly readouts with rising sales (33% last quarter) • Upcoming investor calls/publication strategies may accelerate momentum. ________________________________________ 6. Rhythm Pharmaceuticals (NASDAQ: RYTM) • Catalyst: With FDA-approved Imcivree for genetic obesity, further label expansion or mid-to-late-stage trial results anticipated in 2025 • Institutional buying trends and revenue growth support upcoming readouts . ________________________________________ 7. BeOne Medicines (Ticker: ONC) • Catalyst: Early human data in solid tumor oncology; multiple upcoming trials in 2025 . • Q1 2025 marked first profit; strong institutional support ________________________________________ 8. Mesoblast Ltd & Capricor Therapeutics • Catalyst: Stem-cell therapies targeting GvHD, heart failure, Duchenne muscular dystrophy—key FDA decisions expected in H2 2025 • Maxim Group flags pivotal year for approvals and stock catalysts (marketwatch.com). ________________________________________ 9. Acelyrin (NASDAQ: SLRN) • Catalyst: Phase III results for lonigutamab in thyroid eye disease; shareholder vote on Alumis merger around May 2025 • Merger closing and clinical readouts may drive volatility . ________________________________________ 10. ADC Therapeutics & Foghorn Therapeutics & Pyxis Oncology • Catalysts: Multiple preclinical/early clinical updates presented at AACR (April 2025) o ADC Therapeutics (ADCT): Readouts on 6 ADC programs (Claudin 6, NaPi2b, etc.). o Foghorn (FHTX): Preclinical updates on EP300, FHD609, FHD909. o Pyxis Oncology (PYXS): Phase I ADC and Siglec 15 antibody data. ________________________________________ 🔎 How to Monitor These Catalysts • FDA PDUFA dates (Crinetics, Mesoblast/Capricor, Viking) • Trial readouts/ASC presentations (Kymera, Insmed, ADC Therapeutics, Foghorn, Pyxis) • M&A/news events (BeOne, Acelyrin merger) ________________________________________ 📊 Summary Table Ticker Company Upcoming Catalyst Timeframe CRNX Crinetics PDUFA paltusotine NDA Sep 25, 2025 Viking Viking Therapeutics Injectable Phase III, oral Phase II data From mid-2025 INSM Insmed PAH inhalable Phase III readout Mid-to-late 2025 Kymera Kymera Therapeutics Dermatitis/asthma Phase I → Phase II Late 2025 – 2026 ARQT Arcutis Biotherapeutics Continued quarterly updates Throughout 2025 RYTM Rhythm Pharmaceuticals Label expansion/trial updates 2025 ONC BeOne Medicines Solid tumor trial data 2025 Mesoblast/Capricor Stem-cell stocks FDA decisions H2 2025 SLRN Acelyrin EMA/merger vote + Phase III readout May–Q3 2025 ADCT/FHTX/PYXS AACR presenters Academic readouts on multiple programs April 2025 ________________________________________ ⚠️ A Word of Caution Small-cap biotech involves high volatility—catalyst events often drive sharp price swings, both up and down. Thorough due diligence is essential.
NASDAQ:IBBLong
by ProjectSyndicate
31
IBB d2 accumulation buy/hold setup 40% gains🔸Hello guys, today let's review 2daily chart for IBB . Entering re-accumulation stage now, expecting range bound trading during autumn time season. Range defined by range highs set at 135 usd and range lows at 117 usd. 🔸Similar fractal observed in 2018/2019. Faded into range after heavy spike, re-accumulation then 50% pump later during spring 2020. 🔸Recommended strategy bulls: wait for pullback to complete and reload low near range lows close to 111/113 usd (premium prices). TP1 bulls +20% gains, TP2 bulls +40% gains. buy/hold setup for patient traders. good luck! 🎁Please hit the like button and 🎁Leave a comment to support our team! RISK DISCLAIMER: Trading Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:IBBLong
by ProjectSyndicate
32
IBB Entry, Volume, Target, Stop, ResistanceEntry: with price above 133.81 Volume: with volume greater than 1.67M Target: 138.50 area Stop: Depending on your risk tolerance; Based on an entry of 133.82, 132.25 gets you 3/1 Reward to Risk Ratio. Resistance: 135 area This swing trade idea is not trade advice and is strictly based on my ideas and technical analysis. No due diligence or fundamental analysis was performed while evaluating this trade idea. Do not take this trade based on my idea, do not follow anyone blindly, do your own analysis and due diligence. I am not a professional trader.
NASDAQ:IBBLong
by tradepatiently
Biotech: textbook bullish continuation pattern breakoutBiotech was one of the first sectors in the market to show relative strength and catch some bids throughout the June bottoming process. IBB rallied 20% off the lows and then proceeded to consolidate sideways for 3 weeks. This Wednesday, IBB broke out of that consolidation with a gap up on heavy volume and is now finding more follow-through. Keep an eye on the old Feb/Apr highs around 135 which seems like the next target in this uptrend.
NASDAQ:IBB
by EvanMedeiros
1
IBB Biotech reversal pattern after bounce from TL; low may be inIBB bounced from the green pandemic support zone last March but have came back down to retest this zone. IBB has found support exactly on my GANN FAN line for several times before it breaks down & retested the violet downtrend line & bounced, making a reversal with a long hammer candle. IBB may close today above my GANN FAN line support confirming reversal . Closing the next few days above 124 the pre-pandemic high would give added confidence to the bottom reversal pattern. Next resistances are 127 & 136 to make a higher high. Not trading advice
NASDAQ:IBBLong
by xtremerider8
Can Just One Trade a Day Be Any Good?Everyone wants a trading strategy that allows you to make one trade per day, yet you can still beat the market. Here we explore how you could make one. The Strategy: Gap & Go for Biotech Stocks We decided not to reinvent the wheel and just took the highly popularized "Gap & Go" strategy. The “Gap & Go” is looking for a stock gap up from the previous day's close price with the goal to follow an uptrend. We use biotech stocks as they tend to have higher volatility compared to other industries. You can easily find way more information about the idea and the thesis behind it. We also have a detailed explanation of the enter and exit conditions below. Screening Criteria Biotech Equities (we're using iShares Biotechnology ETF $IBB as a list) Up in the morning 3% or more Are above pre-market high and yesterday’s high Enter Criteria (when to open the position) Stock price is above EMA 9 Stock is going up and EMA 9 is going Exit Criteria(when to close the position) Price crosses below EMA 9 and stays there for 3 bars End of the same day Trailing stop loss of 1.0% Conditions $10,000 trading capital Do not trade early close days Only one trade per day If no equities meet the screening or entry criteria, do not trade The Results: +58% gain over one year Profit $5,801.4 | Wins 48 | Losses 49 Looks pretty decent, but we think that’s just the beginning as we’re going to improve it even further by looking at overall market conditions like $SPY behavior or news. Disclaimer: Not financial / investment advice
NASDAQ:IBBEducation
by BreakingEquity_official
IBB D2: TOPPED OUT // correction looming // SHORT IT!(NEW)Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates IBB D4: TOPPED OUT // correction looming // SHORT IT!(NEW) IMPORTANT NOTE: speculative setup. do your own due dill. use STOP LOSS. don't overleverage. 🔸 Summary and potential trade setup ::: IBB / Biotech sector is maxed out ::: previously a steep 100% run up ::: unsustainable ::: hype is already gone ::: 30/40% correction incoming for IBB ::: VERY limited upside from here ::: rotate out of biotech now ::: expecting correction MODE ::: alternatively you can also SHORT IT ::: SHORT IT 25% gains at least short-term ::: more coming over next few months ::: unsustainable gains, game over now ::: distribution at the TOP setup ::: spells MAJOR trouble for the BULLS ::: BEAR cubs will turn into GRIZZLY ::: expecting CORRECTION to last next 4-8 months ::: distribution at the top in progress ::: will lose up to 40% during correction ::: There is no upside in this market ::: Get out / trim exposure / or SHORT IT ::: Game over bulls and market will shift ::: into BEAR mode September/October 2020 ::: either way setting up for 40%+ correction ::: 4-8 months of correction incoming soon ::: better be prepared in advance ::: when there's GREED there's also PAIN ::: good luck traders 🔸 Supply/Demand Zones ::: N/A ::: N/A 🔸 Other noteworthy technicals/fundies ::: TD9 /Combo update: N/A ::: Sentiment: BEARS ::: Sentiment outlook short-term: BEARISH RISK DISCLAIMER: Trading Crypto, Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:IBBShort
by ProjectSyndicate
3